Pulmozyme
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells. In patients with cystic fibrosis, high concentrations of extracellular DNA are commonly found in the sputum as a result of the body’s innate response to respiratory infections. This increases the viscoelasticity of the mucus, reducing pulmonary function and increasing risk of further infection. Pulmozyme hydrolyzes DNA, reducing the viscoelasticity of sputum and encouraging its clearance.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Pulmozyme : Cystic fibrosis
LIST OF FIGURES
9 Figure 1: Pulmozyme for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Pulmozyme for cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Pulmozyme for cystic fibrosis
13 Figure 4: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
5 Table 1: Pulmozyme drug profile
7 Table 2: Pulmozyme pivotal trial data in cystic fibrosis
14 Table 3: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Orkambi 
Sign up to the